CTOs on the Move

Passage Bio

www.passagebio.com

 
Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.passagebio.com
  • One Commerce Square 2005 Market Street, 39th Floor
    Philadelphia, PA USA 19103
  • Phone: 267.866.0311

Executives

Name Title Contact Details

Funding

Passage Bio raised $115.5M on 02/15/2019
Passage Bio raised $110M on 09/04/2019
Passage Bio raised $154M on 01/21/2021

Similar Companies

MediGene

About MediGene: MediGene AG is a publicly quoted (Frankfurt: Prime Standard), German-American biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market. The company

Insitus Biotechnologies

Insitus Biotechnologies is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspect Biosystems

Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company`s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine.

Genitope Corporation

Genitope Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rapid Pathogen Screening

Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.